Three years, a clinical hold and a death later, Sarepta abandons partnered pivotal-stage gene therapy
Sarepta is breaking off a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on its own as it prepares …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
